The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Unmet needs in high-risk MDS and ongoing trials in the field
Thomas Cluzeau
• 12 Jun 2022
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, highlights some unmet needs in high-risk myelodysplastic syndromes (HR-MDS), drawing focus on the need to improve treatment combinations with azacitidine and ongoing trials evaluating these combinations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
